Fig. 2: Deletion of hepatic ERα impairs glucose tolerance and insulin sensitivity in both DIO male and female mice.
From: An estrogen receptor α-derived peptide improves glucose homeostasis during obesity
a Body weight of ERαF/F and ERαLivKO male mice treated with HFD, n = 6 (ERαF/F) and 9 (ERαLivKO) mice/group. b Body composition of ERαF/F and ERαLivKO male mice treated with HFD, n = 6 (ERαF/F) and 9 (ERαLivKO) mice/group. c Random feeding and 16 h fasting blood glucose in ERαF/F and ERαLivKO male mice treated with HFD, n = 6 (ERαF/F) and 8 (ERαLivKO) mice/group; feeding blood glucose, P = 0.0275; 16 h fasting blood glucose, P = 0.0303. d Glucose tolerance tests in ERαF/F and ERαLivKO male mice treated with HFD, n = 6 (ERαF/F) and 8 (ERαLivKO) mice/group; 0 min, P = 0.0303; 15 min, P = 0.0064; 30 min, P = 0.0008; AUC, P = 0.0149. e Insulin tolerance tests in ERαF/F and ERαLivKO male mice treated with HFD, n = 6 (ERαF/F) and 8 (ERαLivKO) mice/group; 30 min, P = 0.0461; 60 min, P = 0.0443. f Body weight of ERαF/F and ERαLivKO female mice treated with HFD, n = 7 (ERαLivKO) and 10 (ERαF/F) mice/group; P = 0.0494. g Body composition of ERαF/F and ERαLivKO female mice treated with HFD, n = 7 (ERαLivKO) and 10 (ERαF/F) mice/group; fat mass, P = 0.0146; lean mass, P = 0.0115. h Random feeding and 16 h fasting blood glucose in ERαF/F and ERαLivKO female mice treated with HFD, n = 7 (ERαLivKO) and 10 (ERαF/F) mice/group; random feeding blood glucose, P = 0.0006. i Glucose tolerance tests in ERαF/F and ERαLivKO female mice treated with HFD, n = 7 (ERαLivKO) and 10 (ERαF/F) mice/group; 30 min, P = 0.0039; 90 min, P = 0.0340; 120 min, P < 0.0001; AUC, P = 0.0036. j Insulin tolerance tests in ERαF/F and ERαLivKO female mice treated with HFD, n = 7 (ERαLivKO) and 10 (ERαF/F) mice/group; 15 min, P = 0.0088; 45 min, P = 0.0041; 60 min, P = 0.0028. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired Two-tailed Student’s t test. Source data are provided as a Source Data file.
